Patents by Inventor Panduranga A. Reddy

Panduranga A. Reddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rollable screen simultaneous use
    Patent number: 11966260
    Abstract: In aspects of rollable screen simultaneous use, a mobile device includes a rollable display screen configurable in one of multiple display states, including a front-facing portion of the rollable display screen and at least one rear-facing portion of the rollable display screen. The mobile device implements a configuration manager that adjusts content displayed for viewing on the front-facing portion of the rollable display screen based at least in part on a touch actuation to a selectable control on the rear-facing portion of the rollable display screen.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: April 23, 2024
    Assignee: Motorola Mobility LLC
    Inventors: Panduranga Reddy Pailla, Amit Kumar Agrawal, Vijayprakash Bheemsainrao
  • NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20230174570
    Abstract: The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, n, and ring are as defined in formula (I). The invention also relates to novel triterpene derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 8, 2023
    Inventors: Parthasaradhi Reddy BANDI, Rathnakar Reddy KURA, Panduranga Reddy ADULLA, Bhaskar Reddy KASIREDDY
  • Targeted natural language responses for electronic communications
    Patent number: 11436408
    Abstract: A device receives an electronic communication from another device, such as an email. The communication is addressed to multiple recipients and the device determines an association of content in the communication to a user of the device. This association of content to a user can be determined in various manners, such as by identifying one of multiple portions of the communication that is directed to the user rather than other recipients of the communication, determining whether the user is a primary recipient or a secondary recipient of the communication, and so forth. The device generates a set of natural language responses to the communication for the user based at least in part on this association. The device displays the set of natural language responses and receives user selection of one of the natural language responses, then sends the selected natural language response to at least the other device.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: September 6, 2022
    Assignee: Motorola Mobility LLC
    Inventors: Panduranga Reddy Pailla, Vijayprakash Bheemsainrao Idlur, Amit Kumar Agrawal
  • NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20220177439
    Abstract: The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ring are as defined herein. The invention also relates to novel triterpene derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 9, 2022
    Inventors: Parthasaradhi Reddy BANDI, Rathnakar Reddy KURA, Panduranga Reddy ADULLA, Bhaskar Reddy KASIREDDY
  • NOVEL TRITERPENONE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20220144882
    Abstract: The present invention relates to novel triterpenone derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The invention also relates to novel triterpenone derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: February 11, 2020
    Publication date: May 12, 2022
    Inventors: Parthasaradhi Reddy BANDI, Rathnakar Reddy KURA, Panduranga Reddy ADULLA, V L Subrahmanyam LANKA
  • Targeted Natural Language Responses For Electronic Communications
    Publication number: 20220004707
    Abstract: A device receives an electronic communication from another device, such as an email. The communication is addressed to multiple recipients and the device determines an association of content in the communication to a user of the device. This association of content to a user can be determined in various manners, such as by identifying one of multiple portions of the communication that is directed to the user rather than other recipients of the communication, determining whether the user is a primary recipient or a secondary recipient of the communication, and so forth. The device generates a set of natural language responses to the communication for the user based at least in part on this association. The device displays the set of natural language responses and receives user selection of one of the natural language responses, then sends the selected natural language response to at least the other device.
    Type: Application
    Filed: July 1, 2020
    Publication date: January 6, 2022
    Applicant: Motorola Mobility LLC
    Inventors: Panduranga Reddy Pailla, Vijayprakash Bheemsainrao Idlur, Amit Kumar Agrawal
  • C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors
    Patent number: 11034718
    Abstract: The invention relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: June 15, 2021
    Assignee: HETERO LABS LIMITED
    Inventors: Bandi Parthasaradhi Reddy, Gazula Levi David Krupadanam, Adulla Panduranga Reddy, Kasireddy Bhaskar Reddy, Lanka VL Subrahmanyam, Kura Rathnakar Reddy
  • C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors
    Patent number: 10669305
    Abstract: The present invention relates to C-3 novel triterpenone with C-28 urea derivatives of formula (I); or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R1, R2, R3, W, J and X are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) useful for the treatment of viral diseases and particularly HIV mediated diseases.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: June 2, 2020
    Assignee: HETERO LABS LIMITED
    Inventors: Parthasaradhi Reddy Bandi, Rathnakar Reddy Kura, David Krupadanam Gazula Levi, Panduranga Reddy Adulla, Bhaskar Reddy Kasireddy, Carl Thomas Wild, David Eugene Martin, Theodore John Nitz
  • C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20200087342
    Abstract: The invention relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: November 19, 2019
    Publication date: March 19, 2020
    Inventors: Bandi PARTHASARADHI REDDY, Gazula Levi DAVID KRUPADANAM, Adulla PANDURANGA REDDY, Kasireddy BHASKAR REDDY, Lanka VL SUBRAHMANYAM, Kura RATHNAKAR REDDY
  • C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors
    Patent number: 10533035
    Abstract: The invention relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: January 14, 2020
    Assignees: HETERO LABS LTD., DFH THERAPEUTICS, INC.
    Inventors: Bandi Parthasaradhi Reddy, Gazula Levi David Krupadanam, Adulla Panduranga Reddy, Kasireddy Bhaskar Reddy, Lanka Vl Subrahmanyam, Kura Rathnakar Reddy
  • C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
    Patent number: 10370405
    Abstract: The invention relates to C-3 novel triterpenone with C-28 amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases (formula 1).
    Type: Grant
    Filed: March 12, 2016
    Date of Patent: August 6, 2019
    Assignee: HETERO LABS LIMITED
    Inventors: Parthasaradhi Reddy Bandi, Rathnakar Reddy Kura, David Krupadanam Gazula Levi, Panduranga Reddy Adulla, Eswara Rao Bammidi, Bhaskar Reddy Kasireddy, Sudhakar Neela, Carl Thomas Wild, David Eugene Martin, Theodore John Nitz
  • C-3 NOVEL TRITERPENONE WITH C-28 UREA DERIVATIVES AS HIV INHIBITORS
    Publication number: 20180305398
    Abstract: The present invention relates to C-3 novel triterpenone with C-28 urea derivatives of formula (I); or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R1, R2, R3, W, J and X are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) useful for the treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: October 12, 2016
    Publication date: October 25, 2018
    Inventors: Parthasaradhi Reddy BANDI, Rathnakar Reddy KURA, David Krupadanam GAZULA LEVI, Panduranga Reddy ADULLA, Bhaskar Reddy KASIREDDY, Carl Thomas Wild, David Eugene Martin, Theodore John Nitz
  • C-3 NOVEL TRITERPENONE WITH C-28 AMIDE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20180237472
    Abstract: The invention relates to C-3 novel triterpenone with C-28 amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases (formula 1).
    Type: Application
    Filed: March 12, 2016
    Publication date: August 23, 2018
    Inventors: Parthasaradhi Reddy BANDI, Rathnakar Reddy KURA, David Krupadanam GAZULA LEVI, Panduranga Reddy ADULLA, Eswara Rao BAMMIDI, Bhaskar Reddy KASIREDDY, Sudhakar NEELA, Carl Thomas WILD, David Eugene MARTIN, Theodore John NITZ
  • C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20180215780
    Abstract: Formula (I) The invention relates to C-3 novel triterpenone with C-28 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: February 9, 2016
    Publication date: August 2, 2018
    Inventors: Bandi PARTHASARADHI REDDY, Gazula Levi DAVID KRUPADANAM, Adulla PANDURANGA REDDY, Kasireddy BHASKAR REDDY, Lanka VL SUBRAHMANYAM, Kura RATHNAKAR REDDY
  • Betulinic proline imidazole derivatives as HIV inhibitors
    Patent number: 9868758
    Abstract: The present invention relates to novel betulinic proline imidazole derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: January 16, 2018
    Assignee: HETERO LABS LIMITED
    Inventors: Parthasaradhi Reddy Bandi, Rathnakar Reddy Kura, Panduranga Reddy Adulla, David Krupadanam Gazula Levi, Eswara Rao Bammidi, Ranga Reddy, Carl Thomas Wild, David Eugene Martin, Theodore John Nitz
  • NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20170129916
    Abstract: The invention relates to novel betulinic proline substituted derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: June 25, 2015
    Publication date: May 11, 2017
    Applicant: HETERO RESEARCH FOUNDATION
    Inventors: Bandi PARTHASARADHI REDDY, Kura RATHNAKAR REDDY, Gazula Levi DAVID KRUPADANAM, Adulla PANDURANGA REDDY, Bammidi ESWARA RAO, Ranga REDDY
  • NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20170129917
    Abstract: The present invention relates to novel betulinic proline imidazole derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: June 29, 2015
    Publication date: May 11, 2017
    Inventors: Parthasaradhi Reddy Bandi, Rathnakar Reddy Kura, Panduranga Reddy Adulla, David Krupadanam Gazula Levi, Eswara Rao Bammidi, Ranga Reddy
  • C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS
    Publication number: 20170008921
    Abstract: The invention relates to C-3 novel triterpenone with C-28 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    Type: Application
    Filed: February 9, 2016
    Publication date: January 12, 2017
    Applicant: HETERO RESEARCH FOUNDATION
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Gazula Levi David Krupadanam, Adulla Panduranga Reddy, Kasireddy Bhaskar Reddy, Lanka VL Subrahmanyam
  • Fused Tricyclic Compounds as novel mTOR inhibitors
    Patent number: 8609675
    Abstract: The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: December 17, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cliff C. Cheng, Hongbo Zeng, Gerald W. Shipps, Jr., Yongqi Deng, Zhaoyang Meng, Lianyun Zhao, Yang Nan, Binyuan Sun, Duan Liu, Panduranga A. Reddy, M. Arshad Siddiqui
  • FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
    Publication number: 20120178744
    Abstract: The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.
    Type: Application
    Filed: June 30, 2010
    Publication date: July 12, 2012
    Inventors: Cliff C. Cheng, Hongbo Zeng, Gerald W. Shipps, JR., Yongqi Deng, Zhaoyang Meng, Lianyun Zhao, Yang Nan, Binyuan Sun, Duan Liu, Panduranga A. Reddy, M. Arshad Siddiqui